Canine Heartworm Disease: Integrated Prevention, Flea Control, and Diagnostic Management

Introduction

Canine heartworm disease, caused by the filarial nematode Dirofilaria immitis, remains a significant global veterinary concern with expanding geographic distribution driven by climate change and vector dynamics [1, 2, 3]. The disease affects domestic dogs, wild canids, and occasionally cats, with transmission mediated by mosquitoes of the genera Culex, Aedes, and Anopheles [4, 5, 6]. Integrated management strategies combining chemoprophylaxis, vector control, and accurate diagnostics are essential to mitigate disease burden and address emerging macrocyclic lactone (ML) resistance [7, 8, 9]. This review provides an exhaustive examination of the biological, diagnostic, and therapeutic aspects of D. immitis infection, emphasizing the role of combination oral products that target both heartworm and flea infestations (commonly referred to as the "dog heartworm and flea pill").

Etiology and Life Cycle

D. immitis belongs to the family Onchocercidae and requires both a definitive canid host and an intermediate mosquito host to complete its life cycle [10, 11]. Adult worms reside in the pulmonary arteries and right ventricle, where females release microfilariae into the peripheral circulation [12, 13]. Mosquitoes ingest microfilariae during blood meals; within the vector, larvae develop through L1 to L3 stages over approximately 10 to 14 days, depending on ambient temperature [4, 6]. Infective L3 larvae are deposited onto the skin during subsequent feeding and migrate through subcutaneous tissues, undergoing two molts to reach the L5 stage before entering the venous circulation and migrating to the heart and lungs [10, 11]. The prepatent period ranges from 6 to 7 months, after which adult worms produce circulating microfilariae [12, 14].

The intracellular endosymbiont Wolbachia pipientis plays a critical role in worm development, fertility, and host inflammatory responses [1, 15]. Molecular characterization of Wolbachia strains has revealed geographic variability, with implications for pathogenesis and therapeutic targeting [1, 5]. Co-infection with Dirofilaria repens, a subcutaneous filariid, has been documented in endemic regions, complicating clinical presentations and diagnostic interpretation [16, 17, 13].

Epidemiology and Risk Factors

Canine heartworm disease is endemic in tropical, subtropical, and temperate regions, with increasing reports from previously low-prevalence areas due to climate-driven expansion of mosquito habitats [2, 3, 18]. Seroprevalence studies in Sri Lanka, Lebanon, Pakistan, Peru, and Brazil have documented infection rates ranging from 5% to 30% in at-risk populations [1, 19, 14, 20, 21, 22]. Urban and peri-urban environments with high mosquito densities and free-roaming dog populations sustain transmission cycles [5, 18, 23].

Risk factors include lack of chemoprophylaxis, outdoor housing, higher mosquito abundance, and the presence of wildlife reservoirs such as coyotes (Canis latrans) [2, 24]. Studies in Prince Edward Island and Hungary have identified sylvatic cycles that maintain parasite presence even in areas with low domestic dog infection rates [2, 24]. Age, breed, and sex also influence prevalence, with intact male dogs and those older than 2 years showing higher infection rates [25].

Clinical Signs and Pathology

The clinical presentation of heartworm disease correlates with worm burden, duration of infection, and host immune response [12, 25]. Asymptomatic infections are common, particularly in regions with low transmission intensity [14]. Symptomatic dogs typically develop coughing, exercise intolerance, dyspnea, and weight loss due to pulmonary hypertension and right-sided congestive heart failure [12, 26]. In severe cases, caval syndrome (acute right heart failure with hemolysis) can occur when large worm burdens obstruct blood flow through the tricuspid valve [26].

Pathological changes include proliferative endarteritis, pulmonary thromboembolism, and interstitial pneumonia [12, 27]. Renal involvement has been documented in dogs infected with D. repens, manifesting as membranoproliferative glomerulonephritis [16]. Acute respiratory distress may follow adulticide treatment due to thromboembolic events [28]. Clinicopathologic abnormalities include anemia, thrombocytopenia, eosinophilia, and elevated acute-phase proteins such as haptoglobin, which is significantly higher in microfilaremic dogs compared to amicrofilaremic dogs [27].

Diagnostics

Accurate diagnosis of D. immitis infection requires integration of multiple test modalities due to variable antigen and microfilaria dynamics [29].

Antigen Testing

Commercial enzyme-linked immunosorbent assays (ELISAs) targeting adult female worm excretory/secretory antigens are the primary screening tools [29]. Point-of-care (POC) immunochromatographic tests offer rapid results with high specificity, but sensitivity can be reduced in low-burden infections or when antigen is complexed with antibodies [30, 29]. Bayesian latent class modeling estimates the sensitivity of POC tests at 85% to 95% depending on worm burden [29].

Microfilaria Detection

Identification of microfilariae via the modified Knott's test or membrane filtration remains the gold standard for confirming microfilaremia [31, 23]. Microfilariae of D. immitis must be differentiated from D. repens and Acanthocheilonema reconditum based on length, width, and tail morphology [31, 13]. The threshold for detection is approximately 50 to 100 microfilariae per milliliter of blood [31].

Molecular Methods

Polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP) targeting the cytochrome c oxidase subunit I (COI) gene provide high sensitivity and species specificity [32]. Droplet digital PCR (ddPCR) enables quantification of circulating microfilarial DNA and detection of single-nucleotide polymorphisms associated with ML resistance [9]. Quadruplex ddPCR assays can simultaneously detect resistance markers in D. immitis isolates [9]. Molecular screening of mosquito vectors is useful for surveillance and risk mapping [4, 5].

Imaging

Thoracic radiography and echocardiography are used to assess disease severity and guide treatment decisions [26, 17]. Radiographic findings include right ventricular enlargement, pulmonary artery tortuosity, and interstitial lung opacity [26]. Echocardiography can visualize adult worms in the pulmonary arteries and right heart chambers, and is particularly useful in cats [30]. Ultrasonographic detection of motile worms in subcutaneous tissues aids diagnosis of D. repens infection [17].

The following table summarizes key diagnostic methods and their utility:

Diagnostic Algorithm

The following decision tree illustrates an integrated diagnostic approach:

flowchart TD
    A[Clinical suspicion or routine screening], > B{Antigen test}
    B, >|Positive| C{Microfilaria test}
    B, >|Negative| D[Consider occult infection]
    C, >|Positive| E[Confirmed D. immitis infection]
    C, >|Negative| F[Occult infection or low burden]
    D, > G[Repeat antigen test in 3-4 months]
    F, > H[PCR/COI-LAMP if high suspicion]
    E, > I[Assess severity: radiography, echo]
    I, > J[Initiate adulticide or alternative protocol]

Treatment

Therapeutic management of heartworm disease has evolved significantly, with increasing emphasis on non-arsenical protocols due to toxicity concerns and emerging resistance [15, 8].

Adulticide Therapy

Traditional adulticide therapy involves melarsomine dihydrochloride (two or three injections) administered intramuscularly, targeting adult worms [8]. However, melarsomine is associated with pulmonary thromboembolism and injection site reactions [28]. A systematic review and meta-analysis of non-arsenical adulticide protocols using moxidectin (sustained-release injectable or spot-on) combined with doxycycline (to target Wolbachia) demonstrated high efficacy against both adult worms and microfilariae, with reduced adverse events [15]. The combination of doxycycline (10 mg/kg BID for 30 days) and moxidectin (topical or injectable monthly for 6 months) has shown adulticidal efficacy comparable to melarsomine in multiple studies [33, 15, 28].

Microfilaricidal Therapy

Rapid microfilarial clearance is essential to reduce transmission and prevent post-treatment complications [8]. Macrocyclic lactones (ivermectin, moxidectin, selamectin) at monthly prophylactic doses effectively kill microfilariae over several months, but slower kill rates may allow continued transmission [33, 34]. Injectable sustained-release ivermectin formulations have demonstrated high efficacy in preventing infection in endemic areas [33].

Resistance Management

ML resistance in D. immitis has been confirmed in the United States and other regions, characterized by reduced susceptibility of L3 and L4 larvae to prophylactic doses [7, 8, 9]. Resistance is associated with single-nucleotide polymorphisms (SNPs) in the P-glycoprotein gene and other loci [9]. Monthly prophylaxis with higher doses or combination products (e.g., moxidectin plus pyrantel) has been shown to overcome some resistant isolates [7, 34]. A glutamate-gated chloride channel subunit (GLC-2) isolated from D. immitis may serve as a target for novel anthelmintics [35].

Integrated Prevention and Flea Control

Effective heartworm prevention requires a multifaceted approach combining chemoprophylaxis, vector reduction, and owner compliance [33, 34, 29]. The widespread availability of combination oral products that simultaneously prevent heartworm disease and control flea infestations has revolutionized integrated parasite management.

Chemoprophylaxis

Monthly administration of MLs (ivermectin, moxidectin, selamectin) is the cornerstone of heartworm prevention [33, 7, 34]. Sustained-release injectable formulations provide up to 12 months of protection [33]. For dogs with known ML resistance, products containing higher doses of moxidectin or combinations with pyrantel are recommended [7, 34].

The Role of the "Dog Heartworm and Flea Pill"

Combination oral tablets that contain both an ML (for heartworm prevention) and an isoxazoline or other ectoparasiticide (for flea and tick control) have become standard in many regions [7, 34]. These products, often referred to colloquially as the "dog heartworm and flea pill," provide monthly protection against D. immitis, fleas (Ctenocephalides felis), and various tick species. Examples include formulations containing sarolaner/moxidectin/pyrantel or afoxolaner/moxidectin/pyrantel, which have demonstrated high efficacy against ML-resistant isolates [7]. A novel chewable tablet containing lotilaner, moxidectin, praziquantel, and pyrantel (Credelio Quattro) has been approved for heartworm prevention and broad-spectrum parasiticide activity [34]. These combination products simplify administration, improve compliance, and reduce the risk of gaps in prophylaxis.

Flea Control as a Component of Heartworm Prevention

Flea control is integrally linked to heartworm management because mosquitoes are the primary vectors. Environmental mosquito control (removing standing water, using larvicides) and topical or oral insect repellents can reduce exposure [6, 11]. However, flea control itself does not directly prevent heartworm transmission; rather, integrated strategies that target both external parasites and endoparasites are recommended. The use of isoxazoline-containing products for flea control simultaneously reduces stress and pruritus, improving overall patient health [7, 34].

Vector Surveillance and Management

Mosquito surveillance programs that detect D. immitis DNA in wild populations inform timing of chemoprophylaxis and identify high-risk zones [4, 6]. Studies in central Utah used zoo-based mosquito trapping to detect D. immitis in Aedes and Culex species, allowing targeted seasonal prevention [6]. Similar approaches have been applied in Slovenia, Sri Lanka, and Lebanon [4, 5, 18].

Conclusion

Canine heartworm disease remains a dynamic challenge requiring continuous adaptation of diagnostic and preventive strategies. The integration of molecular diagnostics (including ddPCR for resistance profiling), non-arsenical adulticide protocols, and combination oral products that encompass both heartworm and flea control (the "dog heartworm and flea pill") represents the current standard of care. Ongoing surveillance of ML resistance and vector ecology is essential to sustain progress. Future research should focus on novel drug targets, vaccine development, and refinement of point-of-care diagnostics to enable rapid, accurate field detection.

References

[1] Loku Gamage N, Ranasinghe K, Rodrigo W. Molecular Characterization of Wolbachia Endosymbionts and Their Association With Canine Dirofilariasis in Colombo District, Sri Lanka. J Parasitol Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42328691/

[2] Leaman LJ, Graham KF, Jones MEB, et al. First reported case of Dirofilaria immitis in a coyote (Canis latrans) from Prince Edward Island. Can Vet J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42266338/

[3] Aguilar-Elena R, Rodríguez-Escolar I, Collado-Cuadrado M, et al. Global Research Trends in Emerging Zoonosis Due to (the Filarial Nematode) Dirofilaria repens (1955-2025): A Bibliometric Analysis of a Climate-Driven Expansion. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42075713/

[4] Glinšek Biškup U, Knap N, Korva M, et al. Molecular screening of mosquitoes for filarioid helminths in Slovenia. Parasit Vectors. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42083038/

[5] Amarasinghe S, Ranasinghe K, Rodrigo W, et al. First molecular characterization of Dirofilaria vector species and the distribution of canine dirofilariasis in Gampaha district, Sri Lanka. Front Cell Infect Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42064220/

[6] Hammond NG, Todaro A, Fairbanks KA, et al. Mosquito (Diptera: Culicidae) surveillance for Dirofilaria immitis (Rhabditida: Onchocercidae) using a zoo as a focus for operational detection in central Utah. J Med Entomol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41723581/

[7] Rodriguez J, Jones S, Mahabir S, et al. Comparative efficacy of six monthly doses of Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) versus NexGard Plus (afoxolaner, moxidectin, and pyrantel chewable tablets) against a macrocyclic lactone-resistant Dirofilaria immitis isolate in dogs. Parasit Vectors. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42087216/

[8] Geary TG. Current issues in heartworm chemotherapy. Parasit Vectors. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41851772/

[9] Kumar S, Lalicon IK, Prichard RK, et al. Development and evaluation of quadruplex droplet digital PCR assay for rapid detection of molecular markers associated with macrocyclic lactone resistance and susceptibility in Dirofilaria immitis. Int J Parasitol Drugs Drug Resist. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41558254/

[10] Nakhale M, Hess JA, Oliver E, et al. Development of Dirofilaria immitis adult worms in NSG mice, detection of parasite-derived microRNA and comparative analysis of laboratory isolates. Sci Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41617897/

[11] Power RI, Abdullah S, Walden HS, et al. Population genomics reveals an ancient origin of heartworms in canids. Commun Biol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41559308/

[12] Kim M, Seo M, Cho J, et al. Clinicopathologic variables according to disease severity in dogs with heartworm disease. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42152057/

[13] Rajković M, Rajković V, Bogunović D. Dirofilaria immitis and Dirofilaria repens co-infection in a microfilaremic dog from Negotin, Eastern Serbia: Unusual localization of adult Dirofilaria repens in an abdominal hernia sac. Vet Parasitol Reg Stud Reports. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41741045/

[14] Ranahewa DK, Dangolla A, Rajakaruna RS, et al. Subclinical Infections of Babesia and Dirofilaria in Dogs Presented to a Veterinary Teaching Hospital: Evidence for a Silent Reservoir of Infection in Sri Lanka. Acta Parasitol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42113286/

[15] Santiwattanatarm T, Sakcamduang W, Kongkaew C, et al. A systematic review and meta-analysis of non-arsenical adulticide protocols using moxidectin and doxycycline for the treatment of adult heartworm infection in dogs. Curr Res Parasitol Vector Borne Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42007372/

[16] Szabó KÉ, Aresu L, Müller L, et al. Clinico-pathological and renal morphological findings in dogs naturally infected with Dirofilaria repens. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42069630/

[17] Malghem J, Vande Berg B, Lengelé B, et al. Dirofilaria repens Parasite: Review with Emphasis on Ultrasound Findings with Looking for Worm Mobility. J Belg Soc Radiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41909165/

[18] Monteiro ACMP, Ribeiro CM, Fehlberg HF, et al. Emergence of Dirofilaria immitis in humid coastal zones: Epidemiological predictors and molecular characterization. Vet J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41990946/

[19] Khalife S, El Safadi D. Canine vector-borne diseases in Lebanon: Unveiling prevalence trends and risk factors for public health and disease control. Vet Parasitol Reg Stud Reports. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42150803/

[20] Julca LA, Salas-Fajardo MY, Guevara S, et al. Seroprevalence of zoonotic vector-borne pathogens in domestic dogs from rural areas in northern Peru. Top Companion Anim Med. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42035833/

[21] Safdar I, Ur Rehman S, Roman U, et al. Serological and molecular detection of Dirofilaria immitis in pet dogs of Lahore, Pakistan. Ann Parasitol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41881496/

[22] Zanfagnini LG, Chocobar MLE, Schmidt EMS, et al. Unveiling filariid infections in dogs living in the Western Amazon, Brazil. Comp Immunol Microbiol Infect Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41818949/

[23] Roya GM, Yagoob G, Bahram AT. Seasonal study of Blood Parasites: Dirofilaria Immitis and Dipetalonema Reconditum in the Guard Dogs of Tabriz city, Iran. Arch Razi Inst. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41769291/

[24] Nagy E, Nagy RR, Csivincsik Á, et al. Unusually low infection rate of Dirofilaria immitis in its wildlife hosts by the northern border of the Mediterranean climate zone in Hungary. Front Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41487481/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[25] Martínez-Durán D, Mujika M, Morales M, et al. Vector-borne pathogens in Spanish greyhounds from Central Spain: Prevalence and hematobiochemical findings. Vet Parasitol Reg Stud Reports. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41741046/

[26] Stokowski S, Steuri SK, Lux C, et al. Gastric Dilatation and Volvulus and Heartworm Disease in a Dog With Situs Inversus. Vet Radiol Ultrasound. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42011803/

[27] Chocobar MLE, Eckersall DP, Panarese R, et al. Comparison of Haptoglobin Concentrations Between Microfilaremic and Amicrofilaremic Dogs Infected by Dirofilaria immitis. Vet Clin Pathol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41612543/

[28] Nogueira LLDC, Araújo BVS, Antunes JMAP, et al. Blood bronchial mucus with Dirofilaria immitis adult worms after the treatment with doxycycline and moxidectin: a rare case presentation. Parasitology. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41549761/

[29] Atkinson PJ, Quimby C, Datt A, et al. Relative accuracy of point-of-care tests to rule-in heartworm infection in clinically suspected dogs using Bayesian latent class modelling. Prev Vet Med. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41520422/

[30] Nonnis F, Corda A, Zeinoun P, et al. Feline heartworm disease in endemic settings: an integrated diagnostic approach. Res Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42225012/

[31] Sanders TL, Starnes A, Kelly MA, et al. Comparative performance of the novel, point-of-care Pluslife Mini Dock Dirofilaria immitis/Dirofilaria repens detection test with the modified Knott's test in dogs. Parasit Vectors. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42104384/

[32] Genc MG, Erol U, Sahın OF, et al. Application of COI-LAMP for Detection of Dirofilaria immitis with High Sensitivity and Specificity in Epidemiological Studies. Acta Parasitol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41801609/

[33] Genchi M, Venco L, Fozzer M, et al. Efficacy and safety of a sustained-release formulation of ivermectin (FILAPREV) in preventing heartworm infection (Dirofilaria immitis) in dogs in two endemic areas of Italy. Parasit Vectors. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42087229/

[34] Young L, Reinemeyer CR, Abdelmoneim M, et al. Efficacy of a novel chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs. Parasit Vectors. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41943128/

[35] Nichols J, Forrester SG. Isolation and characterization of a novel glutamate-gated chloride channel subunit (GLC-2) from the canine heartworm Dirofilaria immitis. Mol Biochem Parasitol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41581768/